Consistent with this, PD-L1-expressing CTCs have been reported to decrease during ICI treatment in an effective response, increasing upon treatment resistance in NSCLC [18,24,28,30,31], urothelial carcinoma [26], and HCC [29]. The gene discussed is CD274; the disease is hepatocellular carcinoma.